Federal Register / Vol. 83, No. 110 / Thursday, June 7, 2018 / Notices 26503 

Date Document ADAMS Accession No. 

December 17, 2012 ........ Submission of PGEC DFP ..................................................................................................... ML12353A315 

December 17, 2015 ........ Submission of PGEC Triennial DFP ...................................................................................... ML15351A502 

February 1, 2009 ............ Environmental Assessment for Final Rule—Decommissioning Planning ............................. ML090500648 

May 15, 2017 .................. Note to File Re: Section 7 Consultations for ISFSI DFPs ..................................................... ML17135A062 

April 25, 2016 ................. Consultation Letter (ML16120A553–RLSO) .......................................................................... ML17107A273 

April 25, 2016 ................. Letter to M. Fris, U.S. Fish and Wildlife Service Re: NRC Preliminary Determination of No 

Effects Regarding the Diablo Canyon ISFSI DFP.

ML16120A606 

May 11, 2018 .................. Final EA for the Approval of the DFP .................................................................................... ML18131A047 

Dated at Rockville, Maryland, this 4th day 

of June, 2018. 

For the Nuclear Regulatory Commission. 

John McKirgan, 

Branch Chief, Spent Fuel Licensing Branch, 

Division of Spent Fuel Management, Office 

of Nuclear Material Safety and Safeguards. 

[FR Doc. 2018–12249 Filed 6–6–18; 8:45 am] 

BILLING CODE 7590–01–P 

NUCLEAR REGULATORY 

COMMISSION 

Advisory Committee on the Medical 

Uses of Isotopes: Meeting Notice 

AGENCY: Nuclear Regulatory 

Commission. 

ACTION: Notice of meeting. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) will convene a 

teleconference meeting of the Advisory 

Committee on the Medical Uses of 

Isotopes (ACMUI) on July 16, 2018, to 

discuss the draft report of the ACMUI 

Subcommittee on Training and 

Experience Requirements for All 

Modalities. This report will include the 

subcommittee’s comments on the NRC 

staff’s evaluation of the training and 

experience requirements for different 

categories of radiopharmaceuticals in 

Title 10 of the Code of Federal 

Regulations, part 35, ‘‘Medical Use of 

Byproduct Material,’’ Subpart E, 

‘‘Unsealed Byproduct Material—Written 

Directive Required.’’ Meeting 

information, including a copy of the 

agenda and handouts, will be available 

at http://www.nrc.gov/reading-rm/doccollections/acmui/meetings/2018.html. 

The agenda and handouts may also be 

obtained by contacting Ms. Maryann 

Ayoade using the information below. 

DATES: The teleconference meeting will 

be held on Monday, July 16, 2018, 2:00 

p.m. to 4:00 p.m. Eastern Time. 

Public Participation: Any member of 

the public who wishes to participate in 

the teleconference should contact Ms. 

Ayoade using the contact information 

below or may register for the 

GoToWebinar at https://

attendee.gotowebinar.com/register/ 

2201638285137455618. 

Contact Information: Maryann 

Ayoade, email: Maryann.Ayoade@

nrc.gov, telephone: (301) 415–0862. 

Conduct of the Meeting 

Dr. Christopher Palestro, ACMUI 

Chairman, will preside over the 

meeting. Dr. Palestro will conduct the 

meeting in a manner that will facilitate 

the orderly conduct of business. The 

following procedures apply to public 

participation in the meeting: 

1. Persons who wish to provide a 

written statement should submit an 

electronic copy to Ms. Ayoade at the 

contact information listed above. All 

submittals must be received by July 11, 

2018, three business days prior to the 

meeting, and must pertain to the topic 

on the agenda for the meeting. 

2. Questions and comments from 

members of the public will be permitted 

during the meetings, at the discretion of 

the Chairman. 

3. The draft transcript and meeting 

summary will be available on the 

ACMUI’s website http://www.nrc.gov/ 

reading-rm/doc-collections/acmui/ 

meetings/2018.html on or about August 

27, 2018. 

This meeting will be held in 

accordance with the Atomic Energy Act 

of 1954, as amended (primarily Section 

161a); the Federal Advisory Committee 

Act (5 U.S.C. App); and the 

Commission’s regulations in Title 10 of 

the Code of Federal Regulations, part 7, 

‘‘Advisory Committees.’’ 

Dated at Rockville, Maryland, this 4th day 

of June, 2018. 

For the Nuclear Regulatory Commission. 

Russell E. Chazell, 

Federal Advisory Committee Management 

Officer. 

[FR Doc. 2018–12269 Filed 6–6–18; 8:45 am] 

BILLING CODE 7590–01–P 

NUCLEAR REGULATORY 

COMMISSION 

[NRC–2018–0109] 

Draft Letter to the Nuclear Energy 

Institute Regarding the Clarification of 

Regulatory Paths for Lead Test 

Assemblies 

AGENCY: Nuclear Regulatory 

Commission. 

ACTION: Notice of availability; 

opportunity for comment. 

SUMMARY: The U.S. Nuclear Regulatory 

Commission (NRC) is soliciting public 

comments on a draft letter to the 

Nuclear Energy Institute (NEI) clarifying 

the regulatory paths for the use of lead 

test assemblies (LTAs). This draft letter 

would finalize the NRC staff’s views on 

the preliminary positions regarding 

LTAs provided in a letter to NEI dated 

June 29, 2017. The NRC does not 

currently have consolidated regulatory 

guidance regarding the use of LTAs. 

Therefore, the NRC has drafted this 

letter to clarify its positions regarding 

the use of LTAs. These positions would 

affect light-water reactor licensees who 

wish to irradiate LTAs. 

DATES: Submit comments by June 27, 

2018. Comments received after this date 

will be considered if it is practical to do 

so, but the Commission is able to ensure 

consideration only for comments 

received before this date. 

ADDRESSES: You may submit comments 

by any of the following methods: 

• Federal Rulemaking website: Go to 

http://www.regulations.gov and search 

for Docket ID NRC–2018–0109. Address 

questions about NRC dockets to Jennifer 

Borges; telephone: 301–287–9127; 

email: Jennifer.Borges@nrc.gov. For 

technical questions, contact the 

individuals listed in the FOR FURTHER

INFORMATION CONTACT section of this 

document. 

• Mail comments to: May Ma, Office 

of Administration, Mail Stop: TWFN–7– 

A60M, U.S. Nuclear Regulatory 

Commission, Washington, DC 20555– 

0001. 

For additional direction on obtaining 

information and submitting comments, 

see ‘‘Obtaining Information and 


sradovich on DSK3GMQ082PROD with NOTICES